Discover how cutting-edge multi-omics approaches and Generative AI are reshaping oncology drug discovery.
This webinar, led by Michael Ritchie, PhD, MBA, explores how to decode complex tumor cell biology using multi-dimensional deep datasets for biomarker and target discoveries. It is designed for drug discovery scientists, omics researchers, and pharmaceutical professionals eager to stay at the forefront of innovation and accelerate their research.
Key Topics Include:
- Understand why multi-dimensional deep datasets are critical for biomarker and target discovery.
- Learn how to leverage baseline and functional profiling data to deepen insights into tumor cell biology.
- Explore how Generative AI modules, combined with deep datasets, are transforming the drug discovery landscape.
- Categories: Cell & Molecular Biology, Clinical Research, Drug Discovery & Development, Genetics & Genomics, Pharmacology
- Tags: artificial intelligence, genomics, immuno-oncology, large scale proteomics, metabolomics, omics, oncology, proteomics, transciptomics
Presenters
Michael Ritchie, PhD, MBA
Chief Commercial Officer
Champions Oncology
Michael Ritchie, PhD, MBA joined Champions Oncology in July of 2014 and currently serves as Chief Commercial Officer, overseeing all aspects of commercial development, sales and marketing.
Production Partner
Champions Oncology
Champions Oncology is a global preclinical and clinical research services provider that offers end-to-end oncology R&D solutions to biopharma organizations. With the largest and most annotated bank of clinically relevant patient-derived xenograft (PDX) and primary hematological malignancy models, Champions delivers innovative highest-quality data through proprietary in vivo and ex vivo platforms. Through its large portfolio of cutting-edge bioanalytical platforms, groundbreaking data platform and analytics, and scientific excellence, Champions enables the advancement of preclinical and clinical oncology drug discovery and development programs worldwide. For more information, please visit www.ChampionsOncology.com.
Additional Content From Scientist.com
How to Avoid Expensive Redesign Cycles in Antibody Discovery
Learn how integrated antibody discovery and engineering strategies can accelerate the path from hit to optimized lead in less than 12 months while minimizing costly redesign cycles.
Beyond Exposure: Integrating PK/PD for Translational Predictive Power
Learn to integrate PK/PD modeling and strategic biomarkers to bridge the translational gap. Improve clinical predictability for NCEs, ADCs, and large molecules in this technical webinar.
Advancing the Manufacture of Mesenchymal Stromal Cells and Derived Extracellular Vesicles in Stirred-Tank Bioreactors Through Enhanced Bioprocess Control
Learn how to scale the production of MSCs and extracellular vesicles using bioreactor control and real-time monitoring for more consistent therapies.
